Chun-Ming Chen1, Hsuan-Ju Chen2,3, Wei-Shan Chen2,3, Che-Chen Lin4, Chih-Cheng Hsu5,6, Yueh-Han Hsu7,8,9. 1. Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi City, Taiwan. 2. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan. 3. College of Medicine, China Medical University, Taichung, Taiwan. 4. Healthcare Service Research Center, Taichung Veterans General Hospital, Taichung, Taiwan. 5. Institute of Population Health Sciences, National Health Research Institutes, Miaoli County, Taiwan. 6. Department of Family Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan. 7. Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan. 8. Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi City, Taiwan. 9. Department of Nursing, Min-Hwei College of Health Care Management, Tainan City, Taiwan.
Abstract
OBJECTIVE: To determine the clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis (RA). METHODS: The present study was conducted by using the Taiwan National Health Insurance Research Database. In this retrospective nationwide study, we included 3748 RA patients who received influenza vaccinations in 2008, 2009 and 2010, and 3748 matched RA patients who did not receive influenza vaccinations. We followed the patients from 4 weeks after influenza vaccination to the end of the influenza season in each year. After adjustment for potential confounding factors, including disease-modifying anti-rheumatic drugs, we used the Cox proportional hazards regression model to analyze the clinical effectiveness of influenza vaccination. RESULTS: The influenza vaccination rate in RA patients was 14.8% in 2008, 19.8% in 2009 and 9.50% in 2010. Receiving influenza vaccine was associated with reduced risk of hospitalization for septicemia, bacteremia or viremia (hazards ratio [HR] = 0.65, 95% CI = 0.45-0.94), and lower risk of mortality (HR = 0.62, 95% CI = 0.39-0.97). The effectiveness was particularly significant in elderly patients. CONCLUSIONS: RA patients receiving influenza vaccine have significantly lower morbidity and mortality, particularly in elderly patients. Further studies are needed to explore effective policies to increase the vaccination rate in elderly RA patients.
OBJECTIVE: To determine the clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis (RA). METHODS: The present study was conducted by using the Taiwan National Health Insurance Research Database. In this retrospective nationwide study, we included 3748 RApatients who received influenza vaccinations in 2008, 2009 and 2010, and 3748 matched RApatients who did not receive influenza vaccinations. We followed the patients from 4 weeks after influenza vaccination to the end of the influenza season in each year. After adjustment for potential confounding factors, including disease-modifying anti-rheumatic drugs, we used the Cox proportional hazards regression model to analyze the clinical effectiveness of influenza vaccination. RESULTS: The influenza vaccination rate in RApatients was 14.8% in 2008, 19.8% in 2009 and 9.50% in 2010. Receiving influenza vaccine was associated with reduced risk of hospitalization for septicemia, bacteremia or viremia (hazards ratio [HR] = 0.65, 95% CI = 0.45-0.94), and lower risk of mortality (HR = 0.62, 95% CI = 0.39-0.97). The effectiveness was particularly significant in elderly patients. CONCLUSIONS:RApatients receiving influenza vaccine have significantly lower morbidity and mortality, particularly in elderly patients. Further studies are needed to explore effective policies to increase the vaccination rate in elderly RApatients.
Authors: Viviane Ta; Orit Schieir; Marie-France Valois; Ines Colmegna; Carol Hitchon; Louis Bessette; Glen Hazlewood; Carter Thorne; Janet Pope; Gilles Boire; Diane Tin; Edward C Keystone; Vivian P Bykerk; Susan J Bartlett Journal: ACR Open Rheumatol Date: 2022-03-29
Authors: Georgina Nakafero; Matthew J Grainge; Puja R Myles; Christian D Mallen; Weiya Zhang; Michael Doherty; Jonathan S Nguyen-Van-Tam; Abhishek Abhishek Journal: Ann Rheum Dis Date: 2019-04-29 Impact factor: 19.103
Authors: Christien Rondaan; Victoria Furer; Marloes W Heijstek; Nancy Agmon-Levin; Marc Bijl; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha C Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Sander van Assen; Ori Elkayam Journal: RMD Open Date: 2019-09-09